Acute respiratory distress syndrome. by Lunn, J. J. & Murray, M. J.
YALE JOURNAL OF BIOLOGY AND MEDICINE 71 (1998), pp. 457-467.
Copyright © 1999. All rights reserved.
Acute Respiratory Distress Syndrome
Jeffrey J. Lunn and Michael J. Murray
Department ofAnesthesiology, Mayo Medical Center, Rochester, Minnesota
(Received March 24, 1998; accepted August 11, 1998)
HISTORICAL PERSPECTIVES
Although Osler [1], as early as 1925, noted that sepsis resulted in a clinical condition
that we all now recognize as acute respiratory distress syndrome (ARDS)a, it was not until
1967 that Ashbaugh and his colleagues [2] described the first series of these patients
depicting a clinical illness characterized by dyspnea, tachypnea, diffuse pulmonary infil-
trates and profound hypoxemia poorly responsive to oxygen therapy. Pathologic exami-
nation in seven ofthe original 12patients showed pulmonary edema, the formation ofhya-
line membranes and atelectasis.
Because ofits association with shock and trauma, particularly with its increasing inci-
dence in the Vietnam War, it was referred to as "shock lung," "Da Nang lung" and "trau-
matic wet lung." Petty [3] called this condition the "adult respiratory distress syndrome"
which remains its most popular moniker, but because this syndrome is also seen in chil-
dren associated with similaretiologies, aconsensus conference recently recommended the
term "acute respiratory distress syndrome" [4]. In recognition that a spectrum of lung
injury exists, this committee also recommended that the term "acute lung injury" (ALI) be
adopted and that the term "ARDS" be reserved for the most severe form ofALI (Tables 1
and 2).
ETIOLOGY
ARDS is the pulmonary manifestation of many pathophysiologic conditions. Most
commonly, it occurs in the setting of direct lung injury such as aspiration of gastric con-
tents, pneumonitis, pulmonary contusion and near drowning, or secondary to systemic
inflammatory processes such as sepsis, pancreatitis, shock, trauma, etc. Indeed, even
patient care therapies such as oxygen therapy and mechanical ventilation may result in the
development or exacerbation ofthis pulmonary syndrome.
PATHOPHYSIOLOGY
ARDS develops secondary to the activation ofboth cellular and humoral inflammato-
ry mechanisms. Activation ofthese mechanisms results in a process termed the "systemic
inflammatory syndrome" (SIRS) [5], which is poorly understood, but has broad clinical
a To whom all correspondence should be addressed: Jeffrey J. Lunn, M.D., F.C.C.P., Mayo Clinic,
200 First Street, SW, Rochester, MN 55905. Tel.: (507) 255-3280; Fax: (507) 255-4267; E-mail:
lunn.jeffrey@mayo.edu.
bAbbreviations: ARDS, acute respiratory distress syndrome; ALI, acute lung injury; SIRS, systemic
inflammatory syndrome; MODS, multiple organ dysfunction syndrome; DVT, deep venous throm-
bosis; PEEP, positive end-expiratory pressure; CT, computerized tomography; PCOP, pulmonary
capillary occlusion pressure; ECMO, extracorporeal membrane oxygenation; ECCO2R, extra cor-
poreal carbon dioxide removal; IVOX, intravascular oxygenation.
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Table 1. Acute lung injury (ALI) [4].
* Bilateral pulmonary infiltrates on chest x-ray
* Pulmonary capillary wedge pressure <18 mmHg or no clinical evidence suggestive
ofincreased left atrial pressure*
* PaO2 / FiO2<300**
* It is possible to have both ARDS and elevated left atrial pressure coexist.
** Irrespective ofpositive end-expiratory pressure.
Table 2. Acute respiratory distress syndrome [4].
* Bilateral pulmonary infiltrates on chest x-ray
* Pulmonary capillary wedge pressure <18 mmHg or no clinical evidence suggestive
of increased left atrial pressure*
* PaO2 /FiO2 <200**
* It is possible to have both ARDS and elevated left atrial pressure coexist.
** Irrespective ofpositive end-expiratory pressure.
implications with the potential to effect cardiac, hepatic, renal, pulmonary and neurologic
function. When multiple systems are simultaneously impacted, the process is referred to as
"multiple organ dysfunction syndrome" (MODS) [5]. Ofall the organs and systems affect-
ed by this inflammatory response, the lung seems to be the most vulnerable.
The basic science of SIRS and ALI is just beginning to be elucidated. Multiple cell
types, cytokines and othermediators are now known to be involved including neutrophils,
macrophages, lymphocytes, the vascular endothelium complement, interleukins, kinins,
eicosanoids and elements of the coagulation cascade [6-9]. When SIRS affects the lung,
abnormalities of surfactant (decreased production, inactivation [10]) occur, which further
exacerbates pulmonary dysfunction.
Pathologically, ARDS has generally two distinct phases that overlap to some extent.
An exudative phase occurs in the first several days (<7 days) and is characterized by alve-
olar capillary damage with resultant loss of water and protein into the alveolar spaces.
Shortly thereafter, one begins to see hyaline membrane formation. Both processes con-
tribute to the development ofsevere gas exchange abnormalities. Aproliferative stage fol-
lows after about a week and is characterized by interstitial inflammation and the develop-
ment offibrosis.
Ventilator therapy itself can produce and/or exacerbate these pathophysiologic
changes. It is generally recognized that oxygen concentrations greater than 50 to 60 per-
cent may result in the release of leukotrienes, lipid peroxidation and neutrophil aggrega-
tion-all of which damage the lung [11, 12]. In addition, data accumulated over the last
few years have led to the term "volutrauma." It has been shown that alveolar over-disten-
tion from large tidal volumes, and independent of high airway pressures, results in
mechanical changes that induce or worsen lung damage [13, 14]. Integrating this with
Gattinoni's data [15, 16], suggesting areas of lung with relatively normal compliance in
ARDS, has recently led to alterations in the approach to mechanical ventilation in ARDS
to limit the possibility ofover-distention.
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PREVENTION OF ARDS
There are no known preventative therapies. Certainly, however, by attenuating or
eliminating those etiologic processes that result in ARDS, we may be able to decrease its
incidence.
Occasionally gastric aspiration is an inciting event for the development of ARDS.
Lung injury is related to both the volume and pH ofthe aspirated material [17]. About 10
percent ofall patients who clinically aspirate will go on to develop ARDS. When manag-
ing those critically ill patients at risk for gastric aspiration, steps should be taken to
increase gastric pH (H2 blockers and/or nonparticulate antacids), decrease gastric volume
(nasogastric tube suction or prokinetic drugs when indicated) and ensure airway protec-
tion (cricoid pressure during intubation).
Fluid management may also impact the development and coarse of ARDS. Bickell
[18] has shown that early and aggressive fluid resuscitation in patients with penetrating
trauma prior to hospital evaluation contributed to the development ofALI. Additionally,
patients who are over-hydrated have increased morbidity and mortality [19].
The incidence ofARDS should be decreased by: 1) ensuring deep venous thrombo-
sis (DVT) prophylaxis, thereby decreasing pulmonary embolus; 2) elimination of infec-
tion-prone central lines when no longer indicated and decreasing the incidence ofline sep-
sis; 3) utilizing appropriate pulmonary hygiene and decreasing the incidence of pneu-
monitis; 4) feeding enterally when possible with subsequent decrease in bacterial translo-
cation and sepsis; and 5) strict adherence to aseptic technique and avoidance ofinfection.
However, no matter how attentive we are to these details ofpatient care, ARDS will con-
tinue to be seen and will demand our expertise in terms of clinical management and our
commitment to continued investigation into its pathophysiology and potential therapies.
PROGNOSIS
Mortality from ARDS has decreased over the last several years to about 40 to 60 per-
cent [20]. This progress is a result ofthe improvement in supportive care that we now pro-
vide. Pulmonary function in those patients surviving ARDS is remarkably maintained
with the vast majority having normal or near normal pulmonary tests one year later.
Indeed, it is a very small minority who have severe impairment of pulmonary function.
These facts justify aggressive therapy with appropriate optimism in patients with ARDS,
optimism that did not existjust a few years ago.
CURRENT MANAGEMENT OF ARDS
Supportive mechanical ventilation remains the centerpiece of care for patients with
ARDS (Table 3). It must be emphasized, however, that careful attention needs to be direct-
ed towards otherless glamorous aspects ofcare such as adequate intravascularvolume and
Table 3. Current Management Thought in ARDS.
* Lung protection ventilator strategies
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hemoglobin levels, nutrition and associated metabolic factors, DVT prophylaxis, stress
ulcer prophylaxis, avoidance of nosocomial infection and a number of other patient care
details.
ARDS results in many adverse pulmonary abnormalities including an increase in air-
way resistance, adecrease in functional residual capacity and compliance. Thanks to work
by Gattinoni and others, we now recognize that ARDS is not an evenly distributed pul-
monary process [15, 16]. There exists a spectrum ofpulmonary compliance changes with
marked regional differences that result in a "smaller" "normal" lung. Traditional ventila-
tion with large tidal volumes and high peak airway pressures in patients with ARDS can
result in direct lung injury in those areas of lung with normal or relatively normal com-
pliance by preferential delivery ofvolume to those areas and subsequent alveolarover-dis-
tention. It is this over-distention (not high pressure) that appears to injure and exacerbate
lung damage.
This is the basis for recent recommendations regarding mechanical ventilation. The
use oflower tidal volumes (5 to 8 mL/kg) to avoid peak pressures (>35 cm H20), the use
of decelerating waveform for gas delivery, the restriction of FiO2 to maintain acceptable
oxygen saturations (88 to >90 percent) for a given individual, and positive end-expiratory
pressure (PEEP) are mechanical ventilator parameters that are now advocated.
PEEP has been shown to improve oxygenation, increase lung volumes, decrease
shunt fraction and improve pulmonary compliance by a variety ofmechanisms including
redistribution of lung water, increased alveolar volume, recruitment of previously col-
lapsed alveoli, reducing the opening and closing of alveoli with tidal ventilation subse-
quently decreasing shear forces and potentially inhibiting further damage [21-23].
Obviously, PEEP has disadvantages in terms of barotrauma, cardiovascular stability
and potential increases in dead space. This has led to a large number ofdiffering ventila-
tory approaches that have led to "optimal" PEEP, "best" PEEP, "preferred" PEEP, "least"
PEEP and PEEP titrated to minimize dead space. In the absence of compelling evidence
supporting any particular PEEP strategy, it seems prudent to follow a "least" PEEP ther-
apy, which uses the lowest PEEP necessary to maintain acceptable oxygenation with an
FiO2 less than 0.6. With such an approach, there appears to be less interference with
hemodynamics requiring less intravascularvolume and inotropic support and alesserinci-
dence ofpneumothorax.
Permissive hypercapnia
A common adjuvant to the above ventilator strategy is "permissive hypercapnia,"
allowing carbon dioxide to rise (pH >7.2). Described by Hickling [25], there has been
improved survival associated with its use [25-27]. It allows the use of smaller tidal vol-
umes, limited peak pressures and lower rates inherent in lung protection strategies. It is
generally well tolerated if implemented slowly. There are a few patients in whom it can-
not be employed (increased intracranial pressure, ongoing metabolic acidosis, etc.), and in
our experience, it is reasonable therapy.
Pressure-controlled ventilation
Ironically, ventilators became volume cycled to ensure agiven tidal volume inpatients
with poor compliance. We now know that the high pressures that are generated in this
mode in patients with low compliance contributes to, or perhaps even causes, direct lung
damage. This has resulted in a return to pressure-control methods ofventilation using ven-
tilators that at are time cycled and triggered. The advantage ofthese methods is an ability
to maintain but not exceed preset inspiratory pressures. The disadvantages are a varying
flow rate, and depending upon changes in pulmonary compliance, a potentially varying
tidal volume. There is some evidence that there are alveoli recruited by pressure ventila-
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tion that are not recruited when using conventional volume-control methods. Constant
inspiratory pressure, along with PEEP, allows one to arrive at a higher mean airway pres-
sure (the driver for oxygen) at lower peak airway pressures.
These characteristics allow management in such a way as to avoid volutrauma and
barotrauma with greater assurance. It also introduces some additional potential for opera-
tor error, particularly when coupled with inverse I:E ratios, since the result ofincreases in
rate (or decreases in compliance) may actually decrease tidal volume ventilation.
Inverse ratio ventilation
The use ofinverse ratio ventilation is increasing in adults following its successful use
in newborns. The use ofinspiratory times that are equal to or greater than expiration (nor-
mal ratio is 1:2) is said to result in greater alveolar recruitment, leading to alveolar stabi-
lization ofthe lung by not allowing them to collapse below closing volume. Other report-
ed benefits are the ability to decrease peak inspiratory pressures, levels of PEEP, mean
airway pressure and minute ventilation [28, 29]. There is no compelling evidence, how-
ever, that this is the case. Most data suggest that the creation of intrinsic or auto-PEEP
with short expiratory times is responsible for these changes.
Nearly all patients with ARDS being mechanically ventilated will require sedation
and occasionally neuromuscular paralysis. The provision of analgesia and anxiolysis are
appropriate components of compassionate care. The use of neuromuscular blocking
agents remains more controversial, but they can have benefit. Paralysis may decrease oxy-
gen consumption and carbon dioxide production in certain situations. Marked tachypnea
that occurs in these patients has been shown to detract from the beneficial effects ofPEEP
and may need to be controlled by paralysis [30]. Lastly, because ofthe need to control rate
in patients receiving pressure-controlled inverse ratio ventilation (because increasing rate
will decrease expiratory time, decreasing tidal volumes, and potentially producing dan-
gerous levels ofintrinsic PEEP), sedation and paralysis are required.
Figure 1.Left: Computerized tomographic scan of a lung in a patient with ARDS demon-
strating normal areas of the lung and areas with interstitial/alveolar infiltrates. Right: Chest
x-ray ofthe same patient demonstrating diffuse pulmonary edema.
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Position changes
Patient position changes may represent another useful adjunct for improving gas
exchange in ARDS. When one examines computerized tomographic (CT) scans of
patients with ARDS, the nonhomogenous nature is readily apparent, with the majority of
disease in dependent areas (Figure 1). Oxygenation can be improved in the prone position
[31, 32], but turning critically ill patients with multiple tubes and catheters to the prone
position is inherently dangerous. Additionally, no study has yet demonstrated improved
outcome with the prone position.
Early diuresis
Intravascular fluid management can be complex in patients with ARDS, particularly
in patients with trauma or sepsis. There is evidence that pulmonary gas exchange and out-
comes are improved when patients undergo diuresis and fluid restriction with decreasing
pulmonary capillary occlusion pressure (PCOP) and body weight [33-35]. This must be
balanced against potential hypovolemic states that compromise renal or other organ per-
fusion.
EXPERIMENTAL MANAGEMENT OPTIONS IN ARDS
Mortality remains high in ARDS, and the search continues at a rapid pace to find
other ventilator-related and more specific therapies for patients with ARDS (Tables 4 and
5).
Steroids
Two prospective studies have discredited the use of steroids in the early acute care of
patients with ARDS [36, 37]. Recent data have suggested a role for steroids in the prolif-
erative phase ofARDS characterized by fibrosis [38].
Surfactant replacement
As surfactant significantly alters function inARDS, high hopes existed that provision
of this important element exogenously would be beneficial. Unfortunately, this has not










Table 5. Extrapulmonary technology.
* Extracorporeal membrane oxygenation (ECMO)
* Extracorporeal carbon dioxide removal (ECCO2R)
* Intravascular oxygenation (IVOX)
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been proven in ARDS. It is an expensive therapy, one for which there is thus far no evi-
dence of outcome benefit in sepsis-related ARDS [39].
Nitric oxide
Nitric oxide was found in 1987 to be endothelial-deriving relaxing factor [40] and
subsequently shown to act as a selective pulmonary vasodilator when inhaled [41, 42]. It
has no systemic side effects because ofits short half-life. Since it is delivered only to ven-
tilated lung regions, it was suggested that this was a pulmonary vasodilator that would not
increase shunt and, therefore, would be advantageous in ARDS by decreasing pulmonary
artery pressure and enhancing ventilation perfusion matching. Uncontrolled studies con-
firm decreases in pulmonary hypertension and some decrease in pulmonary shunt fraction
and improvement in gas exchange [43, 44].
Despite the enthusiasm following the initial studies, it remains to be seen whether
nitric oxide improves outcome in patients with ARDS or subgroups of patients with
ARDS.
Totallpartial liquid ventilation
Perflubron is a perfluorocarbon that is an inert, colorless liquid. It is an efficient oxy-
gen carrier, has low surface tension and has been reported to have a positive impact on
local inflammatory processes [45, 46]. Clinically, perflubron has been shown to increase
compliance (allowing forlowerairway pressures) and improve oxygenation when instilled
into the lung to functional residual capacity and the patient ventilated with conventional
techniques. It is thought to recruit atelectatic lung, redistribute pulmonary blood flow,
stimulate surfactant production and displace alveolar debris and edema [46, 47].
Experience in adults, however, has been disappointing, and the Food and Drug
Administration recently stopped apediatric trial. The future ofthis technique is unknown.
Ketoconazole
Ketoconazole is an agent that modulates eicosanoid activity, specifically thrombox-
ane and, as such, is ofpotential benefit in ARDS. Although initial results seem encourag-
ing [48], the National Institutes ofHealth's ARDS network was unable to confirm benefit
to ketoconazole.
Antioxidant therapy
The production offree radicals ofoxygen is thought to be a major factor in the patho-
physiology of this process. Animal studies have demonstrated some benefit [49, 50], but
clinical human trials remain inadequate.
Nutritional alterations
Though preliminary, there is evidence that manipulation of mediator formation by
dietary formulas containing high amounts of select fatty acids and antioxidants improves
oxygenation, airway pressure and outcome in animals and humans with ARDS [51, 52].
High-frequency ventilation
High frequency ventilation was initially described in 1972. Its use of small tidal vol-
umes (1-3 mL/kg) and high rates (300-2400 breaths/min) makes it unique in terms ofgas
transport. In the pediatric population, high frequency ventilation has been shown to
improve survival and cause less barotrauma than conventional techniques [53]. In adults,
studies have been mixed with the general consensus that there is no significant advantage
over conventional techniques [54]. Its use continues in adults, usually when all other
efforts to adequately oxygenate the patient have failed.
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Antibody therapy
It has been anticipated that the development of antibodies directed against the major
elements of SIRS (tumor necrosis factor, endotoxin, interleukin, etc.) or receptor antago-
nists wouldresultin improved outcome in the disease states characterized by this response
(sepsis, ARDS, MODS) [55, 56]. Thus far, this approach has proven expensive and inef-
fective. It is likely that the complexity of the inflammatory response is such that there is
not a single "magic bullet" inhibitor that can be used to treatARDS.
Extrapulmonary technologies
These techniques have been developed to provide respiratory support as abridge until
resolution of the patient's ARDS begins to occur, and additionally to "protect" the lungs
from the detrimental effects of more conventional therapies such as oxygen toxicity and
volutrauma. Unfortunately, these techniques are expensive, require additional skilled per-
sonnel and have inherent danger in their use.
Extracorporeal membrane oxygenation (ECMO)
In the 1970s, extracorporeal membrane oxygenation (ECMO) failed to demonstrate a
change in outcome in adults withARDS [57]. Despite this, there is ongoing interest in this
technique, and a few centers continue to use it primarily as a salvage technique when all
other efforts fail [58].
Extracorporeal carbon dioxide removal (ECC02R)
Gattinoni and colleagues used this technique as a means ofproviding carbon dioxide
removal by venovenous bypass [59]. This allowed lower respiratory rates and volumes
with subsequent decreased airway pressure-in short "resting the lungs." Morris [60] and
his group, in aprospective study, could show no additional benefit compared to more con-
ventional therapy using ECCO2 for patients with ARDS.
Intravascular oxygenation (IVOX)
The IVOX is an intravascular oxygenating device that consists of multiple filaments
through which oxygen flows under negative pressure. This device had limited gas
exchange (30 to40 percent oftotal) andrequired anticoagulation [61]. No device currently
exists for clinical use.
CONCLUSION
ARDS is a systemic disease manifested in the lung. Its etiologies are multiple and
varied. At the present time, no specific therapy exists, and care is largely supportive
through the use ofmechanical ventilation, avoidance ofcomplications and therapy direct-
ed towards the initiating problem. Thus far, we have become better at supportive care,
allowing the mortality from ARDS to decrease to as low as 40-60 percent. Most experts
feel this is the limit of improvement that we can expect from improving our approach to
supportive care (avoiding volutrauma, barotrauma, oxygen toxicity and other complica-
tions). Thus, the search continues for more specific therapy and newer interventions such
as partial liquid ventilation, control of the inflammatory response, nitric oxide, and tem-
porary pulmonary replacement therapy (IVOX, ECMO, ECCO2R).
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